

July 18, 2020

Listing Department  
**BSE LIMITED**

**Code: 532 321**

P J Towers, Dalal Street, Fort,  
Mumbai – 400 001

Listing Department

**Code: CADILAHC**

**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai – 400 051

**Re.: Press Release**

Dear Sir/Madam,

Please find enclosed a copy of press release dated July 18, 2020 titled “Zydus Cadila receives final approval from USFDA for Butalbital, Acetaminophen and Caffeine Tablets”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

*Dhaival N. Soni*

**DHAIVAL N. SONI**  
**COMPANY SECRETARY**



**Encl.: As above**

## **Zydus Cadila receives final approval from USFDA for Butalbital, Acetaminophen and Caffeine Tablets**

*Ahmedabad, July 18 2020*

Zydus Cadila has received final approval from the USFDA to market Butalbital, Acetaminophen and Caffeine Tablets (US RLD: Butalbital, Acetaminophen and Caffeine Tablets) in the strengths 50mg/325mg/40 mg.

This combination of medication is used to treat symptom complex of tension (or muscle contraction) headache. The drug will be manufactured at Neshor Pharma's manufacturing facility at St. Louis, USA.

The group now has 294 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

\*\*\*